IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer

KARGI A., YALCIN A. D., ERİN N., SAVAS B., Polat H. H., Gorczynski R. M.

CLINICAL LABORATORY, cilt.58, sa.5-6, ss.501-505, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 58 Sayı: 5-6
  • Basım Tarihi: 2012
  • Dergi Adı: CLINICAL LABORATORY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.501-505
  • Anahtar Kelimeler: Anti-VEGF monoclonal antibody, BevacizumAb, IL8, sTRAIL, PROGNOSTIC-SIGNIFICANCE, TARGETED THERAPIES, CARCINOMA-CELLS, IN-VITRO, EXPRESSION, SULINDAC, INTERLEUKIN-8, RECEPTORS, PROLIFERATION, ANGIOGENESIS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: Colorectal cancer is the third most common human cancer and the third leading cause of cancer related death. BevacizumAb is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancers.